Interview with the CSO of Wintermute Biomedical, Alyce Mayfosh

Wintermute Biomedical is pioneering a next-generation antimicrobial platform that harnesses novel fatty-acid-based micelles to block viral infection and relieve disease symptoms. Its lead candidate, Solexan™, is a first-in-class topical antiviral foam in clinical development for the treatment of shingles and associated pain, with Phase Ib data suggesting meaningful reductions in pain duration compared to placebo. Unlike traditional antivirals that target replication pathways, Solexan™ directly binds to viral particles, preventing entry into host cells and offering a potentially safer and more effective way to manage infection and improve patient outcomes. 

Read Bioneex Story with Wintermute Biomedical here